|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Ri Antibody Screen with Reflex to Titer and Western Blot
Test Code10140
CPT Codes
86255
Includes
If Ri Antibody Screen, IFA is positive, then Ri Antibody, WB will be performed at an additional charge (CPT code(s): 84181).
If Ri Antibody, WB is positive, then Ri Antibody, Titer will be performed at an additional charge (CPT code(s): 86256).
If Ri Antibody, WB is positive, then Ri Antibody, Titer will be performed at an additional charge (CPT code(s): 86256).
Preferred Specimen
1 mL serum
Patient Preparation
Overnight fasting is preferred
Minimum Volume
0.3 mL
Transport Container
Plastic screw-cap vial
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 21 days
Refrigerated: 14 days
Frozen: 21 days
Methodology
Immunofluorescence Assay (IFA) • Western Blot (WB)
FDA Status
This test was developed and its performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.
Setup Schedule
Set up: Mon, Wed, Fri a.m; Report available: 6 days
Reference Range
Ri Ab Screen, IFA | Negative |
Ri Ab, WB | Negative |
Ri Ab, Titer | <1:40 |
Clinical Significance
Anti-Ri can be detected in patients with the paraneoplastic opsoclonus/myoclonus syndrome. Neoplasms most often associated with Anti-Ri include breast cancer, gynecological cancers, and small cell lung cancer.